Hjem › Kronisk myelomonocytisk leukemi
Kliniske studier for Kronisk myelomonocytisk leukemi rekrutterer i USA
42 studier for Kronisk myelomonocytisk leukemi rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX16 studier
- Seattle, WA10 studier
- Boston, MA7 studier
- Baldwin Park, CA6 studier
- New York City, NY6 studier
- Mountain View, CA6 studier
- Rochester, MN6 studier
- Durham, NC5 studier
- Birmingham, AL4 studier
- Miami, FL4 studier
- Atlanta, GA4 studier
- Tampa, FL4 studier
- Columbus, OH4 studier
- Portland, OR3 studier
- Charleston, SC3 studier
- Los Angeles, CA3 studier
- Nashville, TN3 studier
Etter delstat
- Alabama4 studier
- California12 studier
- Florida8 studier
- Georgia4 studier
- Maryland3 studier
- Massachusetts7 studier
- Minnesota7 studier
- New York8 studier
- North Carolina5 studier
- Ohio5 studier
- Oregon3 studier
- Pennsylvania4 studier
- South Carolina3 studier
- Tennessee3 studier
- Texas18 studier
- Washington10 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06904066Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT03418038CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04375631(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT03383575Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07249346Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. aug. 2026 · NCT06523556Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07033598TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
RekruttererFase 1
Alder 18 til 80 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07302776Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
RekruttererFase 2/3Frivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 11. aug. 2026 · NCT04708054Pacritinib in CMML
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06159491Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RekruttererFase 1/2
Alder 12 til 80 · Alle kjønn · Oppdatert 7. aug. 2026 · NCT05092451Personalized NK Cell Therapy in CBT
RekruttererFase 2
Alder 15 til 80 · Alle kjønn · Oppdatert 30. jul. 2026 · NCT02727803Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 20. jul. 2026 · NCT07046078Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT07128381Registry of Older Patients With Cancer
RekruttererObservasjonsstudie
Alder 65 og eldre · Alle kjønn · Oppdatert 29. jun. 2026 · NCT01137825Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT06815003211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RekruttererFase 1/2
Alder 18 til 75 · Alle kjønn · Oppdatert 22. jun. 2026 · NCT03670966Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT05549661Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RekruttererTidlig fase 1
Alder 18 til 75 · Alle kjønn · Oppdatert 3. jun. 2026 · NCT03964506Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
6 Months · Alle kjønn · Oppdatert 29. mai 2026 · NCT04195633Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.